World News Trust World News Trust
World News Trust World News Trust
  • News Portal
  • All Content
    • Edited
      • News
      • Commentary
      • Analysis
      • Advisories
      • Source
    • Flatwire
  • Topics
    • Agriculture
    • Culture
      • Arts
      • Children
      • Education
      • Entertainment
      • Food and Hunger
      • Sports
    • Disasters
    • Economy
    • Energy
    • Environment
    • Government
    • Health
    • Media
    • Science
    • Spiritual
    • Technology
    • Transportation
    • War
  • Regions
    • Africa
    • Americas
      • North America
      • South America
    • Antarctica
    • Arctic
    • Asia
    • Australia/Oceania
    • Europe
    • Middle East
    • Oceans
      • Arctic Ocean
      • Atlantic Ocean
      • Indian Ocean
      • Pacific Ocean
      • Southern Ocean
    • Space
  • World Desk
    • Submit Content
  • About Us
  • Sign In/Out
  • Register
  • Site Map
  • Contact Us
  • Russia's War and the Global Economy | Nouriel Roubini
  • U.S. Considers Radical Rethinking Of Dollar For Today's Digital World | David Gura
  • Why is Israel Amending Its Open-Fire Policy?: Three Possible Answers | Ramzy Baroud
  • WATCH: Republican National Committee Abandons America
  • ‘Previously Unknown Massacres’: Why is Israel Allowed to Own Palestinian History? | Ramzy Baroud
  • The Revolt of the Imagination, Part One: Notes on Belbury Syndrome | John Michael Greer
  • Human gut bacteria have sex to share vitamin B12 | University of California - Riverside

Single CRISPR treatment provides long-term benefits in mice | Duke University

More items by author
Categories
Edited | Front Page Stories | All Content | Health | Science | North America | News | News -- WNT Selected
Tool Bar
View Comments

1These images highlight the stark contrast between mouse models of untreated Duchenne muscular dystrophy (left) and those treated with a CRISPR-based genetic therapy after one year (right). On the right, green indicates a higher level of dystrophin gene expression. The dark spots in the inset show T cells from these mice responding to the bacterial Cas9 protein, indicating the presence of an immune response to the therapy. Credit: Charles Gersbach, Duke University1These images highlight the stark contrast between mouse models of untreated Duchenne muscular dystrophy (left) and those treated with a CRISPR-based genetic therapy after one year (right). On the right, green indicates a higher level of dystrophin gene expression. The dark spots in the inset show T cells from these mice responding to the bacterial Cas9 protein, indicating the presence of an immune response to the therapy. Credit: Charles Gersbach, Duke University

Feb. 18, 2019 (MedicalXpress) -- Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease -- Duchenne muscular dystrophy (DMD) -- for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.

The study appears online Feb. 18 in the journal Nature Medicine.

In 2016, Charles Gersbach, the Rooney Family Associate Professor of Biomedical Engineering at Duke, published one of the first successful uses of CRISPR to treat an animal model of genetic disease with a strategy that has the potential to be translated to human therapy. Many additional examples have since been published, and several genome editing therapies targeting human diseases are currently in clinical trials, with more on the way.

Gersbach's latest research focuses on a mouse model of DMD, which is caused by the body's inability to produce dystrophin, a long protein chain that binds the interior of a muscle fiber to its surrounding support structure.

(more)

READ MORE: MedicalXpress

back to top
  • Created
    Monday, February 18 2019
  • Last modified
    Monday, February 18 2019
  1. You are here:  
  2. Home
  3. All Content
  4. Edited
  5. Single CRISPR treatment provides long-term benefits in mice | Duke University
Copyright © 2022 World News Trust. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.